MIM
RNAC icon

MetLife Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

MetLife Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,667
Closed -$87.9K – 2909
2025
Q1 		$87.9K Hold
6,667
– – ﹤0.01% 2583
2024
Q4 		$119K Buy
+6,667
New +$135K ﹤0.01% 2536
2024
Q3 		– Sell
-2,838
Closed -$76.7K – 2886
2024
Q2 		$76.7K Buy
+2,838
New +$67.7K ﹤0.01% 2692
2023
Q4 		– Sell
-2,073
Closed -$65.9K – 2857
2023
Q3 		$65.9K Hold
2,073
– – ﹤0.01% 2782
2023
Q2 		$69.6K Buy
+2,073
New +$74.2K ﹤0.01% 2848
2022
Q1 		– Sell
-1,203
Closed -$118K – 2765
2021
Q4 		$118K Buy
1,203
+654
+119% +$70.4K ﹤0.01% 2349
2021
Q3 		$68.5K Sell
549
-656
-54% -$79.2K ﹤0.01% 2515
2021
Q2 		$151K Buy
+1,205
New +$143K ﹤0.01% 2320
2020
Q3 		– Sell
-1,190
Closed -$101K – 2329
2020
Q2 		$101K Buy
+1,190
New +$108K ﹤0.01% 2250
2018
Q4 		– Sell
-309
Closed -$144K – 2588
2018
Q3 		$144K Buy
+309
New +$124K ﹤0.01% 2264

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MetLife Investment Management's RNAC Position: Q2 2025 in Review

MetLife Investment Management sold out of Cartesian Therapeutics (RNAC) in Q2 2025, closing a stake of 6,667 shares — an estimated $87.9K sold.

MetLife Investment Management first reported a position in RNAC in Q3 2018 and held it in 10 quarters. The position peaked at $151K in Q2 2021. 66 funds tracked by Wall St. Rank hold RNAC as of Q2 2025.

  • MetLife Investment Management reported no remaining Cartesian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 6,667 Cartesian Therapeutics shares in Q2 2025, an estimated $87.9K.
  • MetLife Investment Management first reported a position in Cartesian Therapeutics in Q3 2018 and held it in 10 quarters.
  • MetLife Investment Management's Cartesian Therapeutics position peaked at $151K in Q2 2021.
  • 66 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.